Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of ACH-0144471 in C3 glomerulopathy or immune-complex MPGN
NL-OMON50417Phase 2Active, not recruiting
- Sponsor
- Achillion Pharmaceuticals
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of danicopan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), sponsored by Achillion Pharmaceuticals. Primary endpoints: Change from baseline in renal biopsy score at 12 months and Proteinuria reduction at 12 months. Started Feb 2019; status: active, not recruiting.
02
Drugs
danicopan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NL-OMON50417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50417.